NCT Number: NCT03468439
Ultrasound and Peripheral Nerve Stimulator Guided Femoral Nerve Block
A pre-post descriptive study was performed to examine the immediate effects of ultrasound (US) guided femoral nerve block with phenol (UGFNBwP) in managing lower limb spasticity of individuals with traumatic spinal cord injury (SCI).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
Study Design: A pre-post descriptive study was performed. Objectives: To examine the immediate effects of ultrasound (US) guided femoral nerve block with phenol (UGFNBwP) in managing lower limb spasticity of individuals with traumatic spinal cord injury (SCI).
Setting: Ankara, Turkey Methods: Nineteen patients with traumatic SCI presenting with lower extremity spasticity were treated with UGFNBwP. Modified Ashworth Scale (MAS) of hip flexion and knee extension, functional independence measure (FIM) motor subscale, difficulty of catheterization (DoC), hygiene score (HS), spasm frequency (SF), sleep quality (SQ) and patient satisfaction (PS) were measured in all patients prior to treatment, at first week and second month.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Traumatic etiology
- Duration of spinal cord injury more than twelve months
- Spasticity of hip flexor and/or knee extensor muscle
- Use of any oral medications to reduce spasticity at stable doses for at least one month before first assessment
- The patients have to accept to continue same dose until end of the last assessment
- Medical clearance to participate
Exclusion criteria
- Having established contracture of the knee/hip joint
- Aged over 65 years
- History of surgery for knee/hip disorders
- Non-traumatic etiology
Treatment and study plan
Primary outcomes
-
Modified Ashworth Scale
Time frame: up to 8 weeks
Scale measures muscle tone (spasticity). (min-max:0-4).Higher values represent a worse outcome.
Secondary outcomes
-
Functional independence measure
Time frame: up to 8 weeks
Scale measures level of independence on activities of daily life (min-max: 0-126) points).Motor subscale of FIM measure is used in this study (min-max:0-91). Higher values represent a better outcome.
Sponsors and collaborators
Lead sponsor
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Other
Registry information
Official study title
Short Term Effect of Ultrasound and Peripheral Nerve Stimulator Guided Femoral Nerve Block With Phenol on Outcomes in People With Traumatic Spinal Cord Injury
Important dates
- Study start
- 2014
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Mar 16, 2018
- Registry last updated
- Mar 16, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI
NCT05589402
Bone Diseases, Brain Diseases
Harlingen, Texas, United States
View Trial DetailsTranscutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder
NCT04350359
Central Nervous System Diseases, Female Urogenital Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsSCED Myokines and Cognition in SCI
NCT05822297
Central Nervous System Diseases, Cognition Disorders
Maastricht, Limburg, Netherlands
View Trial DetailsEpidural and Dorsal Root Stimulation in Humans With Spinal Cord Injury
NCT04736849
Central Nervous System Diseases, Nervous System Diseases
Rochester, Minnesota, United States
View Trial Details